|
Quotes & Info
|
| NLNK > SEC Filings for NLNK > Form 8-K on 4-Jan-2013 | All Recent SEC Filings |
4-Jan-2013
Other Events
On January 3, 2013, NewLink Genetics (NASDAQ:NLNK) announced the appointment of Mr. Brian Wiley as Vice President of Business Development. In addition to business development responsibilities, Mr. Wiley will lead the commercialization strategy and pre-commercial activities for NewLink's HyperAcuteŽ Pancreas Immunotherapy, algenpantucel-L.
The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
|
|